FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
美國食品和藥物管理局授予Petosemtamab的Merus突破性療法稱號，用於治療複發性或轉移性頭頸部鱗狀細胞癌患者
FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
美國食品和藥物管理局授予Petosemtamab的Merus突破性療法稱號，用於治療複發性或轉移性頭頸部鱗狀細胞癌患者
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。